Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Chu

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokineticsRobert J Morgan, James H Doroshow, Timothy Synold, et al.
Human Pathology|May 15, 2014
Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reactionRory L Cochran, Karen Cravero, David Chu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2017
Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma ComponentBracha Erlanger Avigdor, Katie Beierl, Christopher D Gocke, et al.
Oncotarget|August 7, 2015
Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypesRory L Cochran, Justin Cidado, Minsoo Kim, et al.
Clinical Biochemistry|August 4, 2015
Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNAPatricia Valda Toro, Bracha Erlanger, Julia A Beaver, et al.
Cancer Research|September 15, 2017
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and TumorsYuechao Zhao, Mary J Laws, Valeria Sanabria Guillen, et al.
Proteomics|November 5, 2014
A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutationsBrian G Blair, Xinyan Wu, Muhammad Saddiq Zahari, et al.
Breast Cancer Research and Treatment|February 13, 2017
PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneitySarah Croessmann, Hong Yuen Wong, Daniel J Zabransky, et al.
Archives of Otolaryngology--Head & Neck Surgery|April 19, 2006
Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patientsStanley P L Leong, Neil A Accortt, Richard Essner, et al.
Oncotarget|December 26, 2015
TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancerHong Yuen Wong, Grace M Wang, Sarah Croessmann, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokineticsRobert J Morgan, James H Doroshow, Timothy Synold, et al.
Human Pathology|May 15, 2014
Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reactionRory L Cochran, Karen Cravero, David Chu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2017
Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma ComponentBracha Erlanger Avigdor, Katie Beierl, Christopher D Gocke, et al.
Oncotarget|August 7, 2015
Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypesRory L Cochran, Justin Cidado, Minsoo Kim, et al.
Clinical Biochemistry|August 4, 2015
Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNAPatricia Valda Toro, Bracha Erlanger, Julia A Beaver, et al.
Cancer Research|September 15, 2017
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and TumorsYuechao Zhao, Mary J Laws, Valeria Sanabria Guillen, et al.
Proteomics|November 5, 2014
A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutationsBrian G Blair, Xinyan Wu, Muhammad Saddiq Zahari, et al.
Breast Cancer Research and Treatment|February 13, 2017
PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneitySarah Croessmann, Hong Yuen Wong, Daniel J Zabransky, et al.
Archives of Otolaryngology--Head & Neck Surgery|April 19, 2006
Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patientsStanley P L Leong, Neil A Accortt, Richard Essner, et al.
Oncotarget|December 26, 2015
TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancerHong Yuen Wong, Grace M Wang, Sarah Croessmann, et al.
Pageof 12